Video

Dr. Borgen on Surgical Versus Medical Treatment of Breast Cancer

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

Patrick I. Borgen, MD, chair, Department of Surgery, head, Brooklyn Cancer Center, Maimonides Medical Center, compares the efficacy of surgical versus medical treatment of patients with breast cancer.

Although breast cancer has been thought of as a surgical disease for the last several decades, it has evolved to a more medical disease, Borgen explains. This is due to several competing factors, including earlier diagnosis, class prediction through genomic profiling, better characterization of disease, and targeted therapies, and a change in sequencing therapies.

A significant number of patients with breast cancer now begin their course of treatment with medicine, Borgen says. Such therapies have been shown to sterilize locoregional disease in select patients. Today, researchers have a greater understanding regarding the strength of blocking estrogen and endocrine therapies. If applied correctly, these novel agents will be able to achieve superb locoregional control, says Borgen.

<<<

View more from the 2015 CFS Annual Meeting

Related Videos
Ruth M. O’Regan, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Sheldon M. Feldman, MD
Dana Zakalik, MD